Accelerating ADCs’ development pipeline using Simcyp PBPK
With nearly 10 million deaths in 2020 and despite great progress, cancer remains the leading…
Jim Gallagher2021 年 10 月 15 日
PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib
Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating…
Jim Gallagher2021 年 8 月 12 日
DDI Regulatory Poster Child using the Simcyp Simulator: Ibrutinib (Imbruvica®)
Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…
Jim Gallagher2021 年 7 月 29 日
Key Considerations to Ensure Maximal Probability of Antibody Drug Conjugate Development Success
Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an…
Rajesh Krishna2021 年 7 月 8 日
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021 年 5 月 26 日
Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology
Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat…
Jieun Choe2020 年 7 月 14 日
Simcyp: 20 Years of Innovation
The consortium members have partnered with Simcyp and Certara during the past 20 years to…
webdev2019 年 10 月 4 日
